Navigation Links
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Date:12/5/2008

will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the progress and timing of the Company's clinical trials; the potential that earlier clinical trials may not be predictive of future results; the ability for its product candidates to receive regulatory approval on a timely basis or at all; the potential for adverse safety findings relating to its product candidates to delay or prevent regulatory approval or commercialization, or result in product liability claims; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Varian Medical Systems (NYSE: VAR) today broke ground on ... Lake City manufacturing facility and allow for the ... to ultimately create 1,000 new full time jobs ... " Utah is home to hardworking ... can be credited with Varian,s success in the manufacturing of ...
(Date:8/27/2014)... DALLAS , August 27, 2014 ... "Dental Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, ... 2019" published by MarketsandMarkets, the global Dental Equipment Market ... from $5,416.3 million in 2014, growing at a ... Browse 95 market data tables and 61 ...
(Date:8/27/2014)... York , August 27, 2014 ... United States  Laparoscopes Market Outlook to 2020. ... provides key market data on the United States ... of US dollars, volume (in units) and average prices ... Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), Robotic ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5
... , CORALVILLE, Iowa, Dec. 16 Vivakor, ... Development agreement with Baker Consulting out of Walnut Creek, ... of South Florida. Baker Consulting has been retained ... assisting the company with its recently reported acquisition strategy. ...
... Dec. 16 Naurex Inc., a new clinical stage company ... on its novel GFPA NMDA receptor modulators, today announced that ... lead compound GLYX-13 and has successfully dosed the first subjects ... agonist (GFPA) selective modulator of the NMDA receptor, is initially ...
Cached Medicine Technology:Vivakor Signs Business Development Agreement With Baker Consulting 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3
(Date:8/27/2014)... Ticket Down is a dependable ... Levi’s Stadium in Santa Clara. Levi’s Stadium is a ... opened in July and will host their first international soccer ... These are two of the best teams that are both ... will look to continue their successes from the tournament in ...
(Date:8/27/2014)... Texas (PRWEB) August 28, 2014 BRIC ... Outlook to 2020?, provides key market data on the ... of US dollars, volume (in units) and average prices ... Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), Robotic ... are a number of advantages to the patient with ...
(Date:8/27/2014)... August 27, 2014 Michigan Head & Neck ... children of a local elementary school by ensuring they have ... School has year-round attendance, and Michigan Head & Neck Institute ... the new school year. , "There are a lot of ... a great way to give back to our community," said ...
(Date:8/27/2014)... role in inflaming blood vessels and hardening arteries, which ... demonstrates that they may also contribute to pulmonary hypertension, ... vessels in the lungs. , Using a rodent model, ... the main protein in high-density lipoprotein (HDL), the so-called ... lipids in pulmonary hypertension. They also found that reducing ...
(Date:8/27/2014)... Sound Telecom, a leading telecommunications company that offers ... systems, has unveiled an article titled “ Three Things ... .” The piece examines the world of medical messaging ... compliant with HIPAA and HITECH requirements. , Brian ... Sound Telecom, opens with evidence that the use of ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3
... Since mephedrone was made illegal in the UK in 2010, the ... degraded, which in turn may have reduced use of the drug. ... continued to use mephedrone after it became illegal would switch to ... by their friends or on the Internet. They would be ...
... health records (EHRs) are rapidly becoming part of the ... of care. In the first large study of its ... Nursing determined that nurses working with EHRs consistently reported ... for patients than nurses working in hospitals without this ...
... , TUESDAY, Jan. 17 (HealthDay News) -- With the Alzheimer,s ... ages, a panel of experts is meeting for two days ... fast emerging as one of the nation,s biggest -- and ... is to improve diagnosis, buttress support and training programs for ...
... drug called regorafenib slowed the progression of tumors and lengthened ... an international phase III clinical trial found. The findings were ... American Society of Clinical Oncology in San Francisco by ... principal investigator of the trial in the United States. ...
... are performed on all newborns born in the U.S. ... are not apparent at birth. These newborn screening programs ... early and improve outcomes in potentially devastating conditions. ... the data collection linked to newborn screening results, aiming ...
... Jan. 16, 2012 Listen up, pedestrians wearing headphones. ... Many probably can,t, especially young adult males. Serious ... in six years, according to new research from the University ... Medical Center in Baltimore. In many cases, the cars ...
Cached Medicine News:Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 3Health News:Drug improves survival of colorectal cancer patients, trial results show 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 3Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 2Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: